Bioceres Crop Solutions Reports Fiscal Fourth Quarter and Full-Year 2026 Financial and Operating Results
Total revenues were $55.9 million in 4Q26 and $238.3 million in FY26
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal fourth quarter ended June 30, 2026. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted.
Presentation of Results
In January 2026, the Company’s Pro Farm Group (PFG) business was subject to a foreclosure auction. For accounting purposes, PFG has been classified as discontinued operations. The Company disputes the acceleration of the relevant notes and the foreclosure process, which remain subject to ongoing legal proceedings. Accordingly, unless otherwise indicated, the financial results discussed below reflect the Company’s continuing operations for all periods presented, and prior-year amounts have been recast to exclude the PFG business.
Financial & Business Highlights
- Revenues were $55.9 million in 4Q26, broadly stable year-over-year, as 36% growth in Crop Nutrition offset lower Crop Protection revenues and the impact of the Seeds business reconfiguration. FY26 revenues were $238.3 million, down 18%, with approximately half of the decline attributable to the now substantially completed reconfiguration of the Seeds business and the associated reduction in HB4-related activities.
- Gross profit was $12.7 million in 4Q26, compared to $13.6 million in 4Q25, including a $4.0 million non-recurring inventory adjustment arising from an updated assessment of inventory obsolescence. The impact of this adjustment masked improved performance across several core product categories during the quarter. For FY26, gross profit was $82.9 million, down 21%, with improved performance in several core product categories offset by lower contribution from inoculants and higher inventory obsolescence charges.
- SG&A expenses declined by $4.9 million in 4Q26, a 19% year over year reduction, and $22.5 million in FY26 — representing a 24% reduction versus the previous fiscal year. These reductions reflect the cumulative impact of the cost actions implemented during the year.
- Net loss from continuing operations improved to $31.8 million in 4Q26 from $54.4 million in 4Q25, while Adjusted EBITDA1 improved $10.1 million from negative $9.6 million to positive $0.6 million, mainly supported by the materially lower operating expense base. For FY26, net loss from continuing operations was $54.4 million compared to $49.1 million in FY25, while Adjusted EBITDA was $25.5 million compared to $28.9 million
|
1 Please refer to the “Use of non IFRS financial information” section at this end of this document on our use of Adjusted EBITDA and its reconciliation to the most comparable IFRS financial measure. |
Management Review
Mr. Federico Trucco, Bioceres’ Chief Executive Officer, commented: “Fiscal 2026 was a challenging year for Bioceres, marked by the ongoing litigation with certain of our creditors and the resulting business consequences, as we have discussed in our previous reports. Against that backdrop, our priorities have been to focus the business on our core capabilities, reduce our cost structure and strengthen operating discipline. Fourth-quarter results provide encouraging evidence of progress. Revenues from continuing operations were broadly stable year-over-year, with improved performance across several of our core product categories. At the same time, the cost actions implemented throughout the year resulted in a materially lower expense base, allowing us to return to positive Adjusted EBITDA.
“We have now substantially completed the nearly two-year reconfiguration of our Seed business and concluded an external strategic assessment of our continuing operations. That work has provided a clear roadmap for the next phase of the business, including rationalizing our portfolio and go-to market channels, revisiting some of our commercial policies and strategic relationships and re-aligning our R&D&R investments with defined financial objectives, while continuing to explore further efficiencies on the OPEX front.
“These actions are also beginning to translate into improved portfolio profitability, although the benefits are not yet fully reflected in reported gross margin as we work through the portfolio and commercial transitions described above. The performance of several of our core product categories gives us confidence in the direction of these initiatives and their potential to support stronger and more consistent profitability.
“As we enter fiscal 2027, our focus remains on improving the performance and cash generation of our continuing businesses, maintaining cost and working-capital discipline, and actively addressing the Company’s capital structure and liquidity position. We believe the actions taken during fiscal 2026 have established a more focused operating base from which to move forward.”
Key Financial Metrics
Table 1: 4Q26 & FY26 Key Financial Metrics
|
(In millions of U.S. dollars) |
4Q25 |
4Q26 |
%CHANGE |
FY25 |
FY26 |
%CHANGE |
|
Revenue by Segment |
|
|
|
|
|
|
|
Crop Protection |
29.8 |
27.7 |
-7% |
147.1 |
123.7 |
-16% |
|
Seed and Integrated Products |
8.4 |
4.8 |
-43% |
63.9 |
37.7 |
-41% |
|
Crop Nutrition |
17.3 |
23.5 |
36% |
78.5 |
77.0 |
-2% |
|
Total Revenue |
55.4 |
55.9 |
1% |
289.4 |
238.3 |
-18% |
|
Gross Profit |
13.6 |
12.7 |
-6% |
105.0 |
82.9 |
-21% |
|
Gross Margin |
24.6% |
22.8% |
-178 bps |
36.3% |
34.8% |
-151 bps |
|
Operating Expenses |
28.5 |
23.9 |
16% |
103.2 |
82.3 |
20% |
|
|
4Q25 |
4Q26 |
%CHANGE |
FY25 |
FY26 |
%CHANGE |
|
GAAP Net income or loss |
(54.4) |
(31.8) |
42% |
(49.1) |
(54.4) |
-11% |
|
Adjusted EBITDA |
(9.6) |
0.6 |
106% |
28.9 |
25.5 |
-12% |
4Q26 & FY26 Summary:
Revenues from continuing operations were $55.9 million in 4Q26, broadly unchanged from the prior-year quarter, as growth in Crop Nutrition offset lower Crop Protection revenues and the impact of the Seeds business reconfiguration. Gross profit was $12.7 million compared to $13.6 million in 4Q25, as improved performance across several core product categories was offset by higher inventory obsolescence charges.
SG&A expenses declined 19% in the quarter, reflecting reductions in both fixed and variable expenses following cost actions implemented throughout the year. Net loss from continuing operations improved to $31.8 million from $54.4 million in 4Q25, while Adjusted EBITDA improved to $0.6 million from negative $9.6 million.
For FY26, revenues from continuing operations were $238.3 million, down 18%, with approximately half of the decline attributable to the reduction in Seeds and HB4-related activities. Gross profit declined 21% to $82.9 million, with the largest decline in Crop Nutrition, reflecting a lower contribution from the Syngenta agreement, partially offset by improved contribution from microbeaded fertilizers. SG&A expenses declined 24% to $71.2 million, outpacing the reduction in revenues and reflecting the cost actions implemented during the year. Net loss from continuing operations was $54.4 million compared to $49.1 million in FY25, while Adjusted EBITDA was $25.5 million compared to $28.9 million.
For a full version of Bioceres Crop Solutions’ fiscal fourth quarter 2026 and full year 2026 earnings release, click here.
Fiscal Fourth Quarter and Fiscal Year 2026 Earnings Conference Call
Management will host a conference call and question-and-answer session, which will be accompanied by a presentation available during the webcast or accessed via the investor relations section of the company’s website.
To access the call, please use the following information:
|
|
Date: Tuesday, September 15, 2026 |
|
Please dial in 5-10 minutes prior to the start time to register and join. The conference call will be broadcast live and available via the investor relations section of the company’s website here.
|
|
|
|
Time: 8:30 a.m. EDT, 5:30 a.m. PDT |
|
|
|
|
|
US Toll Free dial-in number: 1-833-461-5787 |
|
|
|
|
|
International dial-in numbers: Click here |
|
|
|
|
|
Meeting ID: 858 577 061 |
|
|
|
|
|
Webcast: Click here |
|
|
About Bioceres Crop Solutions Corp.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) is a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change. To do this, Bioceres’ solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices. The company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation Crop Nutrition and Protection solutions. For more information, visit here.
Forward-Looking Statements
This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial data, and any such forward-looking statements involve risks, assumptions and uncertainties. These forward-looking statements include, but are not limited to, statements regarding the Company’s expected operating performance and cash generation, cost and working-capital initiatives, ability to address its capital structure and liquidity needs, refinancing and liability-management activities, the outcome of pending litigation and disputes, and the future performance of its continuing businesses. Such forward-looking statements are based on management’s reasonable current assumptions, expectations, plans and forecasts regarding the company’s current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the company to be materially different from any future results expressed or implied by such forward-looking statements, and there can be no assurance that actual results will not differ materially from management’s expectations or could affect the company’s ability to achieve its strategic goals, including the uncertainties relating to the other factors that are described in the sections entitled “Risk Factors” in the company’s Securities and Exchange Commission filings updated from time to time. The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. All forward-looking statements contained in this release are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are or were made, and the company does not intend to update or otherwise revise the forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, except as required by law.
|
Unaudited Consolidated Statement of Comprehensive Income |
|||||||||
|
(Figures in million of U.S. dollars) |
|||||||||
|
|
Fiscal Year ended 06/30/2026 |
Fiscal Year ended 06/30/2025 |
|
Three-month |
Three-month |
||||
|
Revenues from contracts with customers |
237.8 |
|
287.7 |
|
|
57.0 |
|
55.2 |
|
|
Initial recognition and changes in the fair value of biological assets at the point of harvest |
0.4 |
|
1.8 |
|
|
(1.0 |
) |
0.2 |
|
|
Cost of sales |
(155.4 |
) |
(184.4 |
) |
|
(43.2 |
) |
(41.8 |
) |
|
Gross profit |
82.9 |
|
105.0 |
|
|
12.7 |
|
13.6 |
|
|
% Gross profit |
35 |
% |
36 |
% |
|
23 |
% |
25 |
% |
|
Operating expenses |
(82.3 |
) |
(103.2 |
) |
|
(23.9 |
) |
(28.5 |
) |
|
Share of profit of JV |
0.2 |
|
(1.1 |
) |
|
(0.4 |
) |
0.0 |
|
|
Change in net realizable value of agricultural products |
(0.3 |
) |
(1.5 |
) |
|
(0.0 |
) |
(1.1 |
) |
|
Other income or expenses, net |
(0.7 |
) |
7.4 |
|
|
2.0 |
|
(1.4 |
) |
|
Operating (loss) / profit |
(0.2 |
) |
6.6 |
|
|
(9.6 |
) |
(17.4 |
) |
|
Financial result |
(50.9 |
) |
(53.1 |
) |
|
(20.3 |
) |
(30.6 |
) |
|
Loss before income tax |
(51.0 |
) |
(46.5 |
) |
|
(30.0 |
) |
(47.9 |
) |
|
Income tax |
(3.4 |
) |
(2.6 |
) |
|
(1.8 |
) |
(6.5 |
) |
|
Net loss |
(54.4 |
) |
(49.1 |
) |
|
(31.8 |
) |
(54.4 |
) |
|
(Loss)/Income from discontinued operations |
(179.4 |
) |
(9.7 |
) |
1.3 |
|
2.7 |
||
|
Other comprehensive income / (loss) |
2.5 |
|
(0.7 |
) |
|
2.8 |
|
(0.0 |
) |
|
Total comprehensive income/(loss) |
(231.4 |
) |
(59.6 |
) |
|
(27.7 |
) |
(51.7 |
) |
|
|
|||||||||
|
Net loss from continuing operations attributable to |
|
|
|
|
|
||||
|
Equity holders of the parent |
(46.9 |
) |
(46.2 |
) |
|
(24.5 |
) |
(50.5 |
) |
|
Non-controlling interests |
(3.5 |
) |
(3.6 |
) |
|
(3.0 |
) |
(3.9 |
) |
|
|
(50.4 |
) |
(49.9 |
) |
|
(27.5 |
) |
(54.4 |
) |
|
|
|||||||||
| Weighted average number of shares |
|
|
|
|
|
||||
|
Basic |
63.6 |
63.2 |
|
63.6 |
63.2 |
||||
|
Diluted |
63.6 |
63.2 |
|
63.6 |
63.2 |
Unaudited Consolidated Statement of Financial Position
(Figures in million of U.S. dollars)
|
ASSETS |
30/06/2026 |
30/06/2025 |
||
|
CURRENT ASSETS |
|
|
||
|
Cash and cash equivalents |
11.2 |
32.7 |
||
|
Other financial assets |
1.0 |
2.0 |
||
|
Trade receivables |
98.2 |
165.9 |
||
|
Other receivables |
12.1 |
15.9 |
||
|
Recoverable income tax |
1.4 |
1.9 |
||
|
Inventories |
46.1 |
87.6 |
||
|
Biological assets |
0.6 |
2.4 |
||
|
Assets subject to foreclosure |
44.4 |
– |
||
|
Total current assets |
215.2 |
308.3 |
||
|
NON-CURRENT ASSETS |
|
|
||
|
Other financial assets |
0.0 |
0.0 |
||
|
Trade receivables |
0.7 |
2.5 |
||
|
Other receivables |
24.5 |
23.7 |
||
|
Recoverable income tax |
0.0 |
0.0 |
||
|
Deferred tax assets |
0.3 |
4.9 |
||
|
Investments in joint ventures and associates |
40.8 |
39.4 |
||
|
Investment properties |
– |
0.6 |
||
|
Property, plant and equipment |
60.7 |
74.6 |
||
|
Intangible assets |
82.2 |
181.2 |
||
|
Goodwill |
36.1 |
112.2 |
||
|
Right of use asset |
11.0 |
16.4 |
||
|
Total non-current assets |
256.1 |
455.3 |
||
|
Total assets |
471.3 |
763.6 |
||
|
LIABILITIES |
30/06/2026 |
30/06/2025 |
||
|
CURRENT LIABILITIES |
|
|
||
|
Trade and other payables |
57.6 |
96.4 |
||
|
Borrowings |
47.3 |
119.7 |
||
|
Employee benefits and social security |
4.8 |
6.2 |
||
|
Deferred revenue and advances from customers |
2.1 |
4.3 |
||
|
Income tax payable |
4.9 |
0.5 |
||
|
Consideration for acquisition |
0.0 |
1.8 |
||
|
Secured notes |
118.6 |
102.3 |
||
|
Lease liabilities |
2.1 |
6.9 |
||
|
Liabilities subject to foreclosure |
29.4 |
– |
||
|
Total current liabilities |
267.0 |
338.0 |
||
|
NON-CURRENT LIABILITIES |
|
|
||
|
Trade and other payables |
42.0 |
48.5 |
||
|
Borrowings |
60.0 |
38.2 |
||
|
Deferred revenue and advances from customers |
1.4 |
1.4 |
||
|
Joint ventures and associates |
1.1 |
1.0 |
||
|
Deferred tax liabilities |
20.3 |
30.1 |
||
|
Provisions |
6.2 |
1.3 |
||
|
Consideration for acquisition |
0.4 |
0.4 |
||
|
Secured notes |
– |
– |
||
|
Lease liabilities |
8.8 |
9.5 |
||
|
Total non-current liabilities |
140.2 |
130.4 |
||
|
Total liabilities |
407.2 |
468.4 |
||
|
EQUITY |
|
|
||
|
Equity attributable to owners of the parent |
39.1 |
265.4 |
||
|
Non-controlling interest |
25.0 |
29.8 |
||
|
Total equity |
64.1 |
295.2 |
||
|
Total equity and liabilities |
471.3 |
763.6 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260914032481/en/
Media gallery
